Literature DB >> 6203642

Glioblastoma multiforme: pathology, natural history and treatment.

K A Kelly, J M Kirkwood, D S Kapp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6203642     DOI： 10.1016/0305-7372(84)90014-8

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  18 in total

1.  Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319).

Authors:  A Mittelman; H G Chun; C Puccio; N Coombe; T Lansen; T Ahmed
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  Parotid gland metastasis from glioblastoma multiforme: a case report and review of the literature.

Authors:  Marcel Kraft; Florian Lang; Richard Braunschweig; Robert-Charles Janzer
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-06       Impact factor: 2.503

Review 3.  Neuro-oncology index and review (adult primary brain tumors). Radiotherapy, chemotherapy, immunotherapy, photodynamic therapy.

Authors:  M S Mahaley
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

4.  CCL5, CCR1 and CCR5 in murine glioblastoma: immune cell infiltration and survival rates are not dependent on individual expression of either CCR1 or CCR5.

Authors:  Kien Pham; Defang Luo; Che Liu; Jeffrey K Harrison
Journal:  J Neuroimmunol       Date:  2012-03-16       Impact factor: 3.478

5.  Prognostic factors for high-grade malignant glioma: development of a prognostic index. A Report of the Medical Research Council Brain Tumour Working Party.

Authors: 
Journal:  J Neurooncol       Date:  1990-08       Impact factor: 4.130

6.  Evaluation of pre-radiotherapy cyclophosphamide in patients with newly diagnosed glioblastoma multiforme. Writing Committee for The Brain Tumor Center at Duke.

Authors:  K S Bottom; D M Ashley; H S Friedman; D C Longee
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

7.  The effects of local and systemic interferon beta (Fiblaferon) on supratentorial malignant cerebral glioma--a phase II study.

Authors:  K R von Wild; T H Knocke
Journal:  Neurosurg Rev       Date:  1991       Impact factor: 3.042

8.  Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients.

Authors:  A Boiardi; A Silvani; P A Ruffini; L Rivoltini; G Parmiani; G Broggi; A Salmaggi
Journal:  Cancer Immunol Immunother       Date:  1994-09       Impact factor: 6.968

Review 9.  Multiple extracranial metastases from secondary glioblastoma multiforme: a case report and review of the literature.

Authors:  Li Zhen; Cheng Yufeng; Shao Zhenyu; Xiang Lei
Journal:  J Neurooncol       Date:  2009-11-07       Impact factor: 4.130

10.  Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas.

Authors:  F B Cvitkovic; C Haie-Meder; V Papadimitrakopoulou; J P Armand; C Cioloca; N Maugis; J P Constans
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.